The use of intranasal NEO100 as an agent to treat a neurological disease such as GBM is unique in that it suggests the feasibility of nasal brain delivery via the cranial nerves, thereby avoiding the obstacle presented by the BBB. This delivery method also reduces exposure through the systemic circulation, by that minimizing the systemic side effects. Once the cranial nerve brain delivery method has been fully validated, it may be employed for the delivery of other pharmacologic agents aimed not only at primary brain cancers, but also at secondary brain malignancies/metastases derived from systemic tumors, as well as different neurological diseases, including Parkinson’s, stroke, and Alzheimer’s.

Read The Paper

Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development.

Authors: Thomas C. Chen¹, Clovis O. da Fonseca²and Axel H. Schönthal³

¹Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 USA, ²Department of General and Specialized Surgery, Antonio Pedro University Hospital, Fluminense Federal University, Niterói, RJ 24220, Brazil, ³Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA